• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ADNI 生物统计学核心的贡献。

Contributions of the ADNI Biostatistics Core.

机构信息

Department of Public Health Sciences, University of California, Davis, California, USA.

Department of Neurology, University of Southern California, Los Angeles, California, USA.

出版信息

Alzheimers Dement. 2024 Oct;20(10):7331-7339. doi: 10.1002/alz.14159. Epub 2024 Aug 14.

DOI:10.1002/alz.14159
PMID:39140601
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11485306/
Abstract

The goal of the Biostatistics Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been to ensure that sound study designs and statistical methods are used to meet the overall goals of ADNI. We have supported the creation of a well-validated and well-curated longitudinal database of clinical and biomarker information on ADNI participants and helped to make this accessible and usable for researchers. We have developed a statistical methodology for characterizing the trajectories of clinical and biomarker change for ADNI participants across the spectrum from cognitively normal to dementia, including multivariate patterns and evidence for heterogeneity in cognitive aging. We have applied these methods and adapted them to improve clinical trial design. ADNI-4 will offer us a chance to help extend these efforts to a more diverse cohort with an even richer panel of biomarker data to support better knowledge of and treatment for Alzheimer's disease and related dementias. HIGHLIGHTS: The Alzheimer's Disease Neuroimaging Initiative (ADNI) Biostatistics Core provides study design and analytic support to ADNI investigators. Core members develop and apply novel statistical methodology to work with ADNI data and support clinical trial design. The Core contributes to the standardization, validation, and harmonization of biomarker data. The Core serves as a resource to the wider research community to address questions related to the data and study as a whole.

摘要

阿尔茨海默病神经影像学倡议(ADNI)的生物统计学核心的目标是确保使用合理的研究设计和统计方法来实现 ADNI 的总体目标。我们支持创建一个经过良好验证和精心管理的 ADNI 参与者的临床和生物标志物信息的纵向数据库,并帮助研究人员能够访问和使用该数据库。我们已经开发了一种统计方法,用于描述 ADNI 参与者从认知正常到痴呆的临床和生物标志物变化轨迹,包括多变量模式和认知老化异质性的证据。我们已经应用了这些方法并对其进行了改编,以改进临床试验设计。ADNI-4 将为我们提供一个机会,帮助将这些努力扩展到一个更具多样性的队列,其中包含更丰富的生物标志物数据面板,以支持更好地了解和治疗阿尔茨海默病和相关痴呆症。 亮点:阿尔茨海默病神经影像学倡议(ADNI)生物统计学核心为 ADNI 研究人员提供研究设计和分析支持。核心成员开发并应用新的统计方法来处理 ADNI 数据并支持临床试验设计。核心为生物标志物数据的标准化、验证和协调做出贡献。核心作为资源服务于更广泛的研究社区,以解决与数据和整个研究相关的问题。

相似文献

1
Contributions of the ADNI Biostatistics Core.ADNI 生物统计学核心的贡献。
Alzheimers Dement. 2024 Oct;20(10):7331-7339. doi: 10.1002/alz.14159. Epub 2024 Aug 14.
2
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
3
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).¹⁸F - 氟代脱氧葡萄糖正电子发射断层显像(¹⁸F - FDG PET)用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2.
4
Predicting cognitive decline: Deep-learning reveals subtle brain changes in pre-MCI stage.预测认知衰退:深度学习揭示轻度认知障碍前阶段大脑的细微变化。
J Prev Alzheimers Dis. 2025 May;12(5):100079. doi: 10.1016/j.tjpad.2025.100079. Epub 2025 Feb 6.
5
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.阿尔茨海默病神经影像学计划概述及未来临床试验
Alzheimers Dement. 2025 Jan;21(1):e14321. doi: 10.1002/alz.14321. Epub 2024 Dec 22.
6
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
7
Regional cerebral blood flow single photon emission computed tomography for detection of Frontotemporal dementia in people with suspected dementia.用于检测疑似痴呆患者额颞叶痴呆的局部脑血流单光子发射计算机断层扫描
Cochrane Database Syst Rev. 2015 Jun 23;2015(6):CD010896. doi: 10.1002/14651858.CD010896.pub2.
8
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代硼吡咯进行18F正电子发射断层显像以早期诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
9
The ADNI PET Core at 20.ADNI PET 核心 20 年。
Alzheimers Dement. 2024 Oct;20(10):7340-7349. doi: 10.1002/alz.14165. Epub 2024 Aug 6.
10
Knowledge-driven binning approach for rare variant association analysis: application to neuroimaging biomarkers in Alzheimer's disease.用于罕见变异关联分析的知识驱动分箱方法:在阿尔茨海默病神经影像生物标志物中的应用
BMC Med Inform Decis Mak. 2017 May 18;17(Suppl 1):61. doi: 10.1186/s12911-017-0454-0.

引用本文的文献

1
Longitudinal Analysis of Amyloid PET and Brain MRI for Predicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease: Findings from the ADNI Cohort.淀粉样蛋白PET与脑MRI对预测轻度认知障碍向阿尔茨海默病转化的纵向分析:来自阿尔茨海默病神经影像倡议队列的研究结果
Tomography. 2025 Mar 19;11(3):37. doi: 10.3390/tomography11030037.

本文引用的文献

1
The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research.ADNI4 数字研究:一种用于招募、筛选和评估 AD 临床研究参与者的新方法。
Alzheimers Dement. 2024 Oct;20(10):7232-7247. doi: 10.1002/alz.14234. Epub 2024 Sep 1.
2
Standardized statistical framework for comparison of biomarkers: Techniques from ADNI.标准化的生物标志物比较统计框架:ADNI 的技术。
Alzheimers Dement. 2024 Oct;20(10):6834-6843. doi: 10.1002/alz.14160. Epub 2024 Aug 13.
3
Individuals with Alzheimer's disease and low tau burden: Characteristics and implications.阿尔茨海默病患者和低 tau 负担者:特征和意义。
Alzheimers Dement. 2024 Mar;20(3):2113-2127. doi: 10.1002/alz.13609. Epub 2024 Jan 19.
4
Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection.在数据收集接近中点时,对纵向早发性阿尔茨海默病研究(LEADS)队列进行基线表现分析。
Alzheimers Dement. 2023 Nov;19 Suppl 9(Suppl 9):S8-S18. doi: 10.1002/alz.13160. Epub 2023 May 31.
5
Natural cubic splines for the analysis of Alzheimer's clinical trials.自然三次样条用于阿尔茨海默病临床试验分析。
Pharm Stat. 2023 May-Jun;22(3):508-519. doi: 10.1002/pst.2285. Epub 2023 Jan 10.
6
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4.增加 AD 研究中的参与者多样性:在阿尔茨海默病神经影像学倡议 4 中进行数字筛查、血液检测和社区参与方法的计划。
Alzheimers Dement. 2023 Jan;19(1):307-317. doi: 10.1002/alz.12797. Epub 2022 Oct 9.
7
Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials.预测认知能力下降,以丰富阿尔茨海默病临床试验。
J Prev Alzheimers Dis. 2022;9(3):400-409. doi: 10.14283/jpad.2022.49.
8
Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers.创伤性脑损伤和创伤后应激障碍与使用生物标志物测量的阿尔茨海默病病理无关。
Alzheimers Dement. 2023 Mar;19(3):884-895. doi: 10.1002/alz.12712. Epub 2022 Jun 29.
9
Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology.常染色体显性遗传和散发性晚发性阿尔茨海默病具有共同的体内病理生理学。
Brain. 2022 Oct 21;145(10):3594-3607. doi: 10.1093/brain/awac181.
10
Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia.ATN 生物标志物谱在预测阿尔茨海默病痴呆疾病进展中的预测价值。
Alzheimers Dement. 2021 Nov;17(11):1855-1867. doi: 10.1002/alz.12491. Epub 2021 Nov 10.